pentyl but-3-enoate | 23163-06-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: pentyl but-3-enoate
• 英文别名: but-3-enoic acid pentyl ester；But-3-ensaeure-pentylester；Pentyl 3-butenoate
• CAS: 23163-06-6
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: BUSVERZYRXOWCB-UHFFFAOYSA-N

物化性质

• 沸点：
  188.6±9.0 °C(Predicted)
• 密度：
  0.889±0.06 g/cm3(Predicted)
• 保留指数：
  1049;1065

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  戊醇 、 丁-3-烯酰氯 生成 pentyl but-3-enoate
  参考文献：
  名称：

  Jeffery; Vogel, Journal of the Chemical Society, 1948, p. 663

  摘要：

  DOI：

文献信息

• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• [EN] PROCESS AND COMPOUNDS FOR PREPARATION OF CANNABINOIDS<br/>[FR] PROCÉDÉ ET COMPOSÉS POUR LA PRÉPARATION DE CANNABINOÏDES
  申请人：EMBIO LTD

  公开号：WO2020099942A1

  公开（公告）日：2020-05-22

  The invention involves condensation of various derivatives of cyclic alkene alcohols of Formula (II) or Formula (III) where, R1 is alkyl, aryl, alkyl aryl or heterocyclic carbamoyl. R2 is either R1 as mentioned earlier or an acyl group, -C(=O)-R3 where, R3 is selected from a group comprising (subst)C1-C12 alkyl, (subst)aryl, alkyl aryl with olivetol to get (-)-trans-∆9-tetrahydrocannabinol (also known as Dronabinol, Formula (I)). The process disclosed provides high purity of dronabinol at crude stage making it easy for purification.

  该发明涉及将环烯醇衍生物的各种衍生物进行凝结，其中环烯醇的化学式为(II)或(III)，其中，R1为烷基、芳基、烷基芳基或杂环羰胺。R2可以是前述的R1，也可以是酰基、-C(=O)-R3，其中，R3选自包括(subst)C1-C12烷基、(subst)芳基、烷基芳基的一组化合物，与橄榄酚发生反应，得到(-)-反式-∆9-四氢大麻酚（也称为Dronabinol，化学式(I)）。所披露的方法在原料阶段提供了高纯度的Dronabinol，使其易于纯化。
• Gallium Tribromide Catalyzed Coupling Reaction of Alkenyl Ethers with Ketene Silyl Acetals
  作者：Yoshihiro Nishimoto、Hiroki Ueda、Makoto Yasuda、Akio Baba

  DOI：10.1002/anie.201203778

  日期：2012.8.6

  couple: The α‐alkenylation of esters was accomplished by GaBr3‐catalyzed coupling between alkenyl ethers and ketene silyl acetals. In this reaction system, various alkenyl ethers, including those with vinyl and substituted alkenyl groups, were applicable, and the scope of applicable ketene silyl acetals was sufficiently broad. The mechanism is also discussed.

  A“Ga'llant夫妇：酯的α烯基化物通过贾布尔完成3链烯基醚和甲硅烷基烯酮缩醛之间催化的耦合。在该反应体系中，各种链烯基醚，包括那些具有乙烯基和取代的链烯基，被适用，并适用烯酮甲硅烷基乙缩醛的范围为足够宽。的机理进行了讨论。
• [EN] ARYL ALKYL CARBOXYLIC ACID SALTS, PROCESS FOR PREPARATION AND DOSAGE FORMS<br/>[FR] SELS D’ACIDE ARYLALKYLCARBOXYLIQUE, PROCÉDÉ POUR LEUR PRÉPARATION ET FORMES GALÉNIQUES
  申请人：SHASUN CHEMICALS AND DRUGS LTD

  公开号：WO2011001228A1

  公开（公告）日：2011-01-06

  The invention particularly discloses a process for preparing aryl alkyl carboxylic acid salts by preparing aqueous alkali solution, adding aryl alkyl carboxylic acid to said alkali solution at a temperature ranging from 4° to 121° C for obtaining a clear solution, preferably by heating and/or stirring and concentrating and cooling to obtain aryl alkyl carboxylic acid salt The invention therefore discloses solid oral dosage forms and compositions of aryl alkyl carboxylic acid salts which are free of organic solvent/so. The solid oral dose compositions of aryl alkyl carboxylic acid salts of the invention arc prepared in situ from aryl alkyl carboxylic acids and bases to obtain aryl acid alkyl carboxylic acid sails in crystalline/powder form with or without the use of pharmaceutical excipients.

  该发明特别公开了一种制备芳基烷基羧酸盐的过程，包括制备水溶性碱溶液，在4℃至121℃的温度范围内将芳基烷基羧酸添加到碱溶液中，通过加热和/或搅拌使其变为清澈的溶液，然后浓缩和冷却以获得芳基烷基羧酸盐。因此，该发明公开了不含有机溶剂/酸的芳基烷基羧酸盐的固体口服剂型和组合物。该发明的芳基烷基羧酸盐的固体口服剂型是通过原位制备芳基烷基羧酸和碱来获得晶体/粉末形式的芳酸烷基羧酸盐，可以使用药用辅料来制备。
• ARYL ALKYL CARBOXYLIC ACID SALTS, PROCESS FOR PREPARATION AND DOSAGE FORMS
  申请人：Chodankar Nandkumar

  公开号：US20110144207A1

  公开（公告）日：2011-06-16

  The invention particularly discloses a process for preparing aryl alkyl carboxylic acid salts by preparing aqueous alkali solution, adding aryl alkyl carboxylic acid to said alkali solution at a temperature ranging from 4° to 121° C. for obtaining a clear solution, preferably by heating and/or stirring and concentrating and cooling to obtain aryl alkyl carboxylic acid salt The invention therefore discloses solid oral dosage forms and compositions of aryl alkyl carboxylic acid salts which are free of organic solvent/so. The solid oral dose compositions of aryl alkyl carboxylic acid salts of the invention are prepared in situ from aryl alkyl carboxylic acids and bases to obtain aryl acid alkyl carboxylic acid sails in crystalline/powder form with or without the use of pharmaceutical excipients.

  本发明特别公开了一种制备芳基烷基羧酸盐的方法，包括制备水溶性碱性溶液，将芳基烷基羧酸加入该碱性溶液中，在4℃至121℃的温度范围内获得清晰的溶液，最好通过加热和/或搅拌、浓缩和冷却来获得芳基烷基羧酸盐。因此，本发明公开了不含有机溶剂/酮的芳基烷基羧酸盐的固体口服剂型和组合物。本发明的芳基烷基羧酸盐的固体口服剂型组合物通过从芳基烷基羧酸和碱基中原位制备获得，以获得晶体/粉末形式的芳酸烷基羧酸盐，可以使用药用辅料，也可以不使用。